参考文献/References:
[1] Krajewski JL. P2X3-containing receptors as targets for the treatment of chronic pain[J]. Neurotherapeutics,2020,17(3):826-838.
[2] Wang J,Yu Y. Insights into the channel gating of P2X receptors from structures, dynamics and small molecules[J]. Acta Pharmacol Sin,2016,37(1):44-55.
[3] Jorge CO,de Azambuja G,Gomes BB,et al. P2X3 receptors contribute to transition from acute to chronic muscle pain[J]. Purinergic Signal,2020,16(3):403-414.
[4] Morice AH,Kitt MM,Ford AP,et al. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity:a randomised placebo-controlled study[J]. Eur Respir J,2019,54(1):1900439.
[5] Xue Q,Wang R,Wang L,et al. Downregulating the P2X3 receptor in the carotid body to reduce blood pressure via acoustic gene delivery in canines[J]. Transl Res,2021,227:30-41.
[6] Munoz A,Somogyi GT,Boone TB,et al. Modulation of bladder afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and P2X2/3 receptors[J]. BJU Int,2012,110(8 Pt B):E409-E414.
[7] Marucci G,Dal Ben D,Buccioni M,et al. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications[J]. Expert Opin Ther Pat,2019,29(12):943-963.
[8] Pijacka W,Moraes DJ,Ratcliffe LE,et al. Purinergic receptors in the carotid body as a new drug target for controlling hypertension[J]. Nat Med,2016,22(10):1151-1159.
[9] Wang Y,Li G,Liang S,et al. Role of P2X3 receptor in myocardial ischemia injury and nociceptive sensory transmission[J]. Auton Neurosci,2008,139(1-2):30-37.
[10] Zhang J,Liu S,Xu B,et al. Study of baicalin on sympathoexcitation induced by myocardial ischemia via P2X3 receptor in superior cervical ganglia[J]. Auton Neurosci,2015,189:8-15.
[11] Sheng X,Dan Y,Dai B,et al. Knockdown the P2X3 receptor in the stellate ganglia of rats relieved the diabetic cardiac autonomic neuropathy[J]. Neurochem Int,2018,120:206-212.
[12] Shi L,Zhang HH,Hu J,et al. Purinergic P2X receptors and diabetic neuropathic pain[J]. Sheng Li Xue Bao,2012,64(5):531-542.
[13] Spinaci A,Buccioni M,Dal Ben D,et al. P2X3 Receptor Ligands:Structural Features and Potential Therapeutic Applications[J]. Front Pharmacol,2021,12:653561.
[14] Browne LE,Jiang LH,North RA. New structure enlivens interest in P2X receptors[J]. Trends Pharmacol Sci,2010,31(5):229-237.
[15] Lewis C,Neidhart S,Holy C,et al. Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons[J]. Nature,1995,377(6548):432-435.
[16] Sterle I,Zupan?i? D,Romih R. Correlation between urothelial differentiation and sensory proteins P2X3, P2X5, TRPV1, and TRPV4 in normal urothelium and papillary carcinoma of human bladder[J]. Biomed Res Int,2014,2014:805236.
[17] Vandenbeuch A,Larson ED,Anderson CB,et al. Postsynaptic P2X3-containing receptors in gustatory nerve fibres mediate responses to all taste qualities in mice[J]. J Physiol,2015,593(5):1113-1125.
[18] Song X,Gao X,Guo D,et al. Expression of P2X(2) and P2X(3) receptors in the rat carotid sinus, aortic arch, vena cava, and heart, as well as petrosal and nodose ganglia[J]. Purinergic Signal,2012,8(1):15-22.
[19] Yokoyama T,Saino T,Nakamuta N,et al. Three-dimensional architectures of P2X2-/P2X3-immunoreactive afferent nerve terminals in the rat carotid body as revealed by confocal laser scanning microscopy[J]. Histochem Cell Biol,2016,146(4):479-488.
[20] Kuan YH,Shyu BC. Nociceptive transmission and modulation via P2X receptors in central pain syndrome[J]. Mol Brain,2016,9(1):58.
[21] Liu S,Zhang C,Shi Q,et al. Puerarin blocks the signaling transmission mediated by P2X3 in SG and DRG to relieve myocardial ischemic damage[J]. Brain Res Bull,2014,101:57-63.
[22] Ma H,Meng J,Wang J,et al. Targeted delivery of a SNARE protease to sensory neurons using a single chain antibody (scFv) against the extracellular domain of P2X(3) inhibits the release of a pain mediator[J]. Biochem J,2014,462(2):247-256.
[23] Burnstock G. Purinergic signalling:therapeutic developments[J]. Front Pharmacol,2017,8:661
[24] Trzebski A,Tafil M,Zoltowski M,et al. Increased sensitivity of the arterial chemoreceptor drive in young men with mild hypertension[J]. Cardiovasc Res,1982,16(3):163-172.
[25] Moraes DJA,da Silva MP,Spiller PF,et al. Purinergic plasticity within petrosal neurons in hypertension[J]. Am J Physiol Regul Integr Comp Physiol,2018,315(5):R963-R971.
[26] Gu QR,Li YY,Chen GR,et al. The arteriolar injury in hypertension[J]. Med Hypotheses,2018,111:66-69.
[27] Imamura T,Ishizuka O,Zhong C,et al. An extract (THC-002) of Ba-Wei-Die-Huang-Wan inhibits expression of tachykinins, and P2X3 and TRPV1 receptors, and inhibits ATP-induced detrusor overactivity in spontaneously hypertensive rats[J]. Neurourol Urodyn,2009,28(6):529-534.
[28] Fu LW,Tjen-A-Looi SC,Barvarz S,et al. Role of opioid receptors in modulation of P2X receptor-mediated cardiac sympathoexcitatory reflex response[J]. Sci Rep,2019,9(1):17224.
[29] Shao LJ,Liang SD,Li GL,et al. Exploration of P2X3 in the rat stellate ganglia after myocardial ischemia[J]. Acta Histochem,2007,109(4):330-337.
[30] Wang Y,Li G,Yu K,et al. Expressions of P2X2 and P2X3 receptors in rat nodose neurons after myocardial ischemia injury[J]. Auton Neurosci,2009,145(1-2):71-75.
[31] Li G,Liu S,Yang Y,et al. Effects of oxymatrine on sympathoexcitatory reflex induced by myocardial ischemic signaling mediated by P2X3 receptors in rat SCG and DRG[J]. Brain Res Bull,2011,84(6):419-424.
[32] Xu X,Liu B,Yang J,et al. Glucokinase in stellate ganglia cooperates with P2X3 receptor to develop cardiac sympathetic neuropathy in type 2 diabetes rats[J]. Brain Res Bull,2020,165:290-297.
[33] Wang HJ,Li YL,Gao L,et al. Alteration in skeletal muscle afferents in rats with chronic heart failure[J]. J Physiol,2010,588(Pt 24):5033-5047.
[34] Wang Y,Hu H,Yin J,et al. TLR4 participates in sympathetic hyperactivity Post-MI in the PVN by regulating NF-κB pathway and ROS production[J]. Redox Biol,2019,24:101186.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(2):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(2):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(2):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(2):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(2):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(2):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(2):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(2):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]